Results 181 to 190 of about 79,249 (245)

Advances in selective targeting of serine hydrolases: A targeted covalent approach against hCES2A mitigates irinotecan toxicity <i>in vivo</i>. [PDF]

Acta Pharm Sin B
De Vita E.
europepmc   +1 more source

Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report. [PDF]

J Pharm Health Care Sci
Kanno R, Saito Y, Takekuma Y, Harada K, Komatsu Y, Sugawara M.   +5 more
europepmc   +1 more source

KLF13-mediated CES2 upregulation via p300-dependent acetylation sensitizes gastric cancer cells to irinotecan. [PDF]

iScience
Zhang HB, Hu RH, Zhang KH, Cui XM, Zhang S.   +4 more
europepmc   +1 more source

Pathological Response of Locally Recurrent Rectal Cancer to Neoadjuvant Chemoradiotherapy. [PDF]

J Anus Rectum Colon
Yokoyama Y, Ozaki K, Nozawa H, Sasaki K, Murono K, Emoto S, Kaneko K, Matsuzaki H, Abe S, Nagai Y, Shinagawa T, Ishihara S.   +11 more
europepmc   +1 more source

Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies. [PDF]

ACS Nano
Nel AE, Luo L, Liao YP, Wang X.
europepmc   +1 more source

Loss-of-function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5-fluorouracil and irinotecan treatment in colorectal cancer. [PDF]

Clin Transl Med
Queralt C, Moreta-Moraleda C, Costa M, Grau-Leal F, Diesch J, Vendrell-Ayats C, Musulén E, Wright RHG, Bugés C, Manzano JL, Cabrero-de Las Heras S, Zuber J, Buschbeck M, Forcales SV, Martínez-Balibrea E.   +14 more
europepmc   +1 more source

Interventional Radiotherapy (Brachytherapy) Combined with Systemic Treatment-The Influence of RAS Gene Mutations and Combined Therapy on the Results and Toxicity of Colorectal Cancer Liver Metastases. [PDF]

Cancers (Basel)
Cisek P, Kozłowska A, Grzybowska-Szatkowska L.   +2 more
europepmc   +1 more source

Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. [PDF]

Cancer Commun (Lond)
Zhang Z, Sun X, Liu A, Zhu Y, Zhang T, Liu L, Jia J, Tan S, Wu J, Wang X, Zhou J, Yang J, Zhang C, Zhang H, He X, Cai G, Huang C, Xia F, Wan J, Zhang H, Shen L, Wang L, Zhang W, Cai S, Zhu J.   +24 more
europepmc   +1 more source

Second-line 5-FU plus nanoliposomal irinotecan versus FOLFOX/XELOX in metastatic pancreatic cancer after gemcitabine-nab-paclitaxel failure: a propensity score-matched analysis. [PDF]

ESMO Open
Trovato G, Rossini D, Guidolin A, Su YY, Shan YS, Chiang NJ, Chou WC, Bai LY, Bagalà C, Bensi M, Niger M, Marchesi S, Garattini SK, Michelotti A, Pretta A, Scartozzi M, Vivaldi C, Bartalini L, Procaccio L, Bergamo F, Antonuzzo L, Chen LT, Salvatore L, Tortora G.   +23 more
europepmc   +1 more source